ArticleFrontiers in cellular and infection microbiology2012
Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders.
Article in Frontiers in cellular and infection microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 57 citations in OpenAlex.
- Glanders: Past, Present and Future of a Neglected Zoonosis as a Threat in Veterinary and Human Health.Veterinary medicine and science · 2026Review
- Mortality among hospitalized children with melioidosis in Thailand: a retrospective national database analysis (2015-2023).The Lancet regional health. Southeast Asia · 2025Article
- Melioidosis vaccines: recent advances and future directions.Frontiers in immunology · 2025Review
- Comparison of homologous and heterologous vaccination strategies for combating disease caused byFrontiers in immunology · 2025Article
- Development of an Antigen Capture Lateral Flow Immunoassay for the Detection ofDiagnostics (Basel, Switzerland) · 2024Article
- Identification ofMicrobiology spectrum · 2024Article
- Burkholderia pseudomallei and melioidosis.Nature reviews. Microbiology · 2024Review
- Use of Reductive Amination to Produce Capsular Polysaccharide-Based Glycoconjugates.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Prospective Analysis of Antibody Diagnostic Tests and TTS1 Real-Time PCR for Diagnosis of Melioidosis in Areas Where It Is Endemic.Journal of clinical microbiology · 2023Article
- Pathogenicity and virulence ofVirulence · 2022Review
- Functional Activities of O-Polysaccharide and Hemolysin Coregulated Protein 1 Specific Antibodies Isolated from Melioidosis Patients.Infection and immunity · 2022Article
- Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive Burkholderia pseudomallei AhpC.Infection and immunity · 2022Article
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- Layered and integrated medical countermeasures againstFrontiers in microbiology · 2022Article
- Evaluation of antigen-detecting and antibody-detecting diagnostic test combinations for diagnosing melioidosis.PLoS neglected tropical diseases · 2021Article
- Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines.NPJ vaccines · 2021Article
- Combating the great mimicker: latest progress in the development ofExpert review of vaccines · 2020Review
- Distinct classes and subclasses of antibodies to hemolysin co-regulated protein 1 and O-polysaccharide and correlation with clinical characteristics of melioidosis patients.Scientific reports · 2019Article
- Impact of Binge Alcohol Intoxication on the Humoral Immune Response duringMicroorganisms · 2019Article
- Novel multi-component vaccine approaches for Burkholderia pseudomallei.Clinical and experimental immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Burkholderia pseudomallei and Burkholderia mallei, the etiologic agents of melioidosis and glanders, respectively, cause severe disease in humans and animals and are considered potential agents of biological warfare and terrorism. Diagnosis and treatment of infections caused by these pathogens can be challenging and, in the absence of chemotherapeutic intervention, acute disease is frequently fatal. At present, there are no human or veterinary vaccines available for immunization against these emerging/re-emerging infectious diseases. One of the long term objectives of our research, therefore, is to identify and characterize protective antigens expressed by B. pseudomallei and B. mallei and use them to develop efficacious vaccine candidates. Previous studies have demonstrated that the 6-deoxy-heptan capsular polysaccharide (CPS) expressed by these bacterial pathogens is both a virulence determinant and a protective antigen. Consequently, this carbohydrate moiety has become an important component of the various subunit vaccines that we are currently developing in our laboratory. In the present study, we describe a reliable method for isolating CPS antigens from O-polysaccharide (OPS) deficient strains of B. pseudomallei; including a derivative of the select agent excluded strain Bp82. Utilizing these purified CPS samples, we also describe a simple procedure for covalently linking these T-cell independent antigens to carrier proteins. In addition, we demonstrate that high titer IgG responses can be raised against the CPS component of such constructs. Collectively, these approaches provide a tangible starting point for the development of novel CPS-based glycoconjugates for immunization against melioidosis and glanders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.